Difference between revisions of "Mitoxantrone (Novantrone)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf#page=36 Mitoxantrone (Novantrone) package insert PDF page 36-41]<ref name="insert"></ref> | *[http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf#page=36 Mitoxantrone (Novantrone) package insert PDF page 36-41]<ref name="insert"></ref> | ||
*[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mitoxantrone.asp Mitoxantrone (Novantrone) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mitoxantrone-patient-drug-information Mitoxantrone (Novantrone) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *12/23/1987: Initial FDA approval for the initial treatment of acute nonlymphocytic leukemia (ANLL) | ||
| + | *11/13/1996: Approved in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory [[Prostate cancer | prostate cancer]]. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Irritant chemotherapy]] | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
| + | |||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| + | [[Category:Acute promyelocytic leukemia medications]] | ||
| + | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
| + | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
| + | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Hodgkin lymphoma medications]] | ||
| + | [[Category:Mantle cell lymphoma medications]] | ||
| + | [[Category:Marginal zone lymphoma medications]] | ||
| + | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1987]] | ||
Revision as of 04:01, 18 July 2014
General information
Class/mechanism: Synthetic antineoplastic anthracenedione, intercalates into DNA, causing crosslinking and strand breaks. Mitoxantrone inhibits topoisomerase II, which helps to uncoil and repair damaged DNA. It also has been observed to interfere with RNA and has activity against resting and proliferating cells. In vitro, it has been observed to interfere with antigen presentation; inhibit B-cell, T-cell, and macrophage proliferation; and decrease secretion of interferon gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2).[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Mitoxantrone (Novantrone) package insert PDF page 36-41[1]
- Mitoxantrone (Novantrone) patient drug information (Chemocare)[3]
- Mitoxantrone (Novantrone) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/23/1987: Initial FDA approval for the initial treatment of acute nonlymphocytic leukemia (ANLL)
- 11/13/1996: Approved in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.
References
Categories:
- Chemotherapy
- Irritant chemotherapy
- Anthracyclines
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Aggressive Non-Hodgkin lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Follicular lymphoma medications
- Hodgkin lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Prostate cancer medications
- Drugs FDA approved in 1987